Over 370 centrally authorized products have been transferred to new rapporteurs located in the remaining 27 EU member states, Iceland, and Norway. The transfer followed a procedure developed by the EMA’s working groups on committees’ operational preparedness for both human and veterinary medicines in the wake of the United Kingdom’s withdrawal from the European Union.
The European Union and the European Medicines Agency (EMA) recently announced completion of the reallocation of the United Kingdom’s duties for evaluating medicines.
According to the reallocation report, over 370 centrally authorized products have been transferred to new rapporteurs located in the remaining 27 EU member states, Iceland, and Norway. The transfer followed a procedure developed by the EMA’s working groups on committees’ operational preparedness for both human and veterinary medicines in the wake of the United Kingdom’s withdrawal from the European Union.
The redistribution plan applies to medicines that have already been granted marketing authorization, and, according to the EMA, “follows a multifaceted approach and takes into account both the diverse expertise in the European medicines regulatory network and the workload associated with each medicine.”
The following principles were utilized by the EMA Management Board to guide the redistribution of the product portfolio:
The approach used for the redistribution of medicines was based on member states’ knowledge and expertise with specific classes of medicines. In addition, the transfer process also took into account the type of product that was being reallocated. For example, generic medicines were allocated to NCAs that have indicated that they would like increased involvement with evaluating such medicines.
Finally, groups of products with the same international non-propriety name, or products that belong to the same marketing authorization holder, have been reallocated to a single rapporteur in order to efficiently facilitate the review of post-authorization procedures.
The identities of the new rapporteurs will be communicated to the marketing authorization holders by the end of April 2018, and the rapporteurs will take full responsibility of the newly transferred products as of March 30, 2019, when the United Kingdom officially withdraws from the European Union.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
BioRationality—The Evolution of the BPCIA and the Bright Future of Biosimilars in the US
October 7th 2024The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar development, but regulatory reforms over the years have drastically reduced costs and approval times, with further advancements expected by 2025 that will foster competition and drive down prices.